A Plasmid-Based Cancer Therapy - Dr. Alexander Schneider

In this episode of the Talking Biotech podcast, host Dr. Kevin Folta engages with Dr. Alex Schneider, CEO and founder of CureLab, to discuss innovative approaches to cancer treatment, particularly focusing on the challenges posed by refractory cancers such as triple-negative breast cancer and platinum-resistant ovarian cancer. Dr. Schneider emphasizes the evolution of cancer therapies from traditional chemotherapy to more sophisticated immunotherapies, highlighting the importance of understanding immune responses in combating cancer. He introduces Elanogen, a plasmid-based therapy designed to enhance immune presentation and combat chronic inflammation, which can hinder the effectiveness of conventional treatments like gemcitabine.

The conversation delves into the mechanisms of Elanogen, explaining how it targets the P62 protein, which is overproduced in cancer cells, making them vulnerable to immune attacks. Dr. Schneider shares insights from clinical trials, noting the promising results of combining Elanogen with standard chemotherapy, and discusses future applications of this therapy in various cancers and even non-cancerous diseases associated with chronic inflammation. The episode concludes with a call for intellectual humility in science, as both hosts reflect on the evolving nature of cancer research and the potential for new discoveries in the field.